Document is current

Article History

Received: 2 August 2024

Accepted: 28 August 2024

First Online: 5 September 2024

Declarations

:

: <b>Sina Zaic</b>: declares no conflict of interest relevant to this study.<b>Nik Krajnc</b>: has participated in meetings sponsored by, received speaker honoraria or travel funding from Alexion, BMS/Celgene, Janssen-Cilag, Merck, Novartis, Roche and Sanofi-Genzyme and held a grant for a Multiple Sclerosis Clinical Training Fellowship Programme from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).<b>Stefan Macher</b>: declares no conflict of interest relevant to this study.<b>Martin Michl</b>: declares no conflict of interest relevant to this study.<b>Nina Müller</b>: declares no conflict of interest relevant to this study.<b>Christoph Mitsch</b>: declares no conflict of interest relevant to this study.<b>Wolfgang Marik</b>: declares no conflict of interest relevant to this study.<b>Klaus Novak</b>: declares no conflict of interest relevant to this study.<b>Christian Wöber</b>: has received honoraria consultancy/speaking from Apomedica, Curelator.<b>Berthold Pemp</b>: declares no conflict of interest relevant to this study.<b>Gabriel Bsteh</b>: has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene/BMS, Novartis, Roche, Sanofi-Genzyme and Teva. He has received unrestricted research grants from Celgene/BMS and Novartis.